JW Seo and IW Park. INTRAVITREAL BEVACIZUMAB FOR TREATMENT OF DME been applied once in 4 eyes and more than twice in 4 eyes. Full scatter panretinal laser therapy had been performed on 15 eyes (50%), and 6 eyes (20%) had undergone pars plana vitrectomy. Previous intravitreal injection of triamcinolone acetonide had been performed on 4 eyes at least 3 months before undergoing intravitreal bevacizumab injection. Addi- tional baseline characteristics by treatment group are depicted in Table 1. Improvements in visual acuity were noted from 1 week after intravitreal bevacizumab injection, and these statistically significant changes continued throughout the 3-month follow- up visit (Fig. 1). At baseline, the mean BCVA was 0.73±0.36 logMAR. This improved significantly to 0.63±0.41 (p=0.02), 0.58±0.36 (p=0.003), and 0.61±0.40 logMAR (p=0.006) at 1 week, 1 month, and 3 months, respectively. At 3-month follow-up, the BCVA was slightly decreased, but there was no significant difference in the mean BCVA between the 1- and 3-month follow-up visits (p=0.536). The visual acuity results are summarized in Figure 2. Final BCVA analysis by subgroup demonstrated that 15 (50%) of 30 eyes remained stable, 12 (40%) improved ≥2 lines on BCVA, and 3 (10%) deteriorated ≥2 lines on BCVA (Table 2). Mean central retinal thickness was 498.96±123.99 µm (range, 275-733 µm) at baseline by OCT. At 1 week post- operatively, the mean central retinal thickness measurement decreased to 359.06±105.97 µm (p<0.001), and this signi- ficant improvement of retinal thickening continued through the 1- and 3-month follow-up visits (p<0.001 and p=0.035, First Week No. of Eyes Percentage 2 7% 17 57% 11 37% First Month No. of Eyes Percentage 1 3% 16 53% 13 43% Third Month No. of Eyes Percentage 3 10% 15 50% 12 40% B Fig. 1. Changes in best-corrected visual acuity (BCVA) and central retinal thickness measured by optical coherence tomography (OCT) after intravitreal bevacizumab injection. Thirty eyes (28 patients) with a minimum of 3 months follow-up were included for analysis. The mean patient age was 57.9±13.8 years, and 60% were male (18 men, 12 women). All patients completed 3 months of follow-up, with a mean follow-up period of 5.26±2.39 months (range, 3-11 months). Type 2 diabetes was present in 83.3% of patients, and type 1 diabetes was present in 16.7% of patients. Eighteen eyes (60%) exhibited PDR, and twelve exhibited severe nonpro- liferative diabetic retinopathy (NPDR). Twenty-five eyes (83.3%) had received at least one alternative therapy before intravitreal bevacizumab injection. Focal laser therapy had Table 2. Best-corrected visual acuity (BCVA) analysis Decreased ≥2 lines of BCVA Remained stable Improved ≥2 lines of BCVA A Fig. 2. Development of visual acuity (logMAR) evaluated after 1 month (A) and 3 months (B) of follow-up. 19